Invasive aspergillosis (IA) is associated with significant morbidity and mortality, and, among other factors, this is due to a delay in diagnosis performed with conventional techniques. A prospective, multicentre study was conducted to evaluate the efficacy of Aspergillus D N A screening in the early diagnosis of IA. Patients undergoing haematopoietic stem cell transplantation or chemotherapy for acute leukaemia were enrolled for biomarker screening. Three centres applied the same protocol for in-house PCR, which was compliant with the European Aspergillus PCR Initiative recommendations, to guarantee the highest diagnostic standards. Two thousand one hundred and twenty-eight sera from 2 13 patients were investigated and stratified according to the revised European Organization for the Research and Treatment of Cancer/Mycoses Study Group criteria for invasive fungal disease. The incidence rates of probable and possible IA were 18% and 38%, respectively. The sensitivity, specificity and positive predictive value (PPV) of PC R were superior in antifungal drug-naive patients, being 71.4%, 92.3%, and 62.5%, respectively. The last of these key performance indicators (PPV) was moderate in patients receiving primary prophylaxis, at 5.4%. Negative predictive values for both strategies applied were 100% with and 98.3% without antifungal mould prophylaxis. PCR has the potential to play a decisive role in the diagnosis and management of Aspergillus infections in centres not applying primary antifungal mould prophylaxis.
Introduction
Invasive aspergillosis (IA) is a common opportunistic fungal infection, and usually occurs in immunocompromised patients.
Early diagnosis is critical for a favourable outcome, but is difficult to achieve with conventional methods. Hence, a range of mo lecular and serological techniques have been investigated. The detection of galactomannan (G M ) via Platelia Aspergillus enzyme immunoassay (EIA ) has been incorporated into the diagnostic criteria for IA, but its specificity and sensitivity vary from 40% to 100%, and depend on the population tested [1, 2] . Measurement of blood ( 1, 3) -(3-D-glucan may be useful as a preliminary screening tool, but this antigen is a pan-fungal marker. The sensitivities and specificities in patients with haematological malignancies and IA ranged from 55% to 95% and from 77% to 96%, respectively [3 -5 ] . Recently, the Aspergillus Lateral Flow
Device was shown to be as accurate as the standard serological marker GM [6] . The detection of Aspergillus D N A lacks technical standardization, and a relatively poor understanding of D N A release prevents its broad application. Various PC R assays have been developed, and the sensitivities and specificities range from 43% to 100% and from 64% to 100%, respectively [7] [8] [9] [10] [11] [12] [13] [14] , N o t a single nucleic acid-based molecular test has yet provided enough accuracy to be incorporated into expert guidelines [15, 16] , This multicentre study applied prospective biomarker-based screening in patients at risk for IA, using an identical protocol for PCR, which was compliant with the European Aspergillus PC R Initiative (EA P C R I) [17] recommendations to guarantee the highest diagnostic standards and to enhance PC R performance for the diagnosis of IA. The performance of biomarker screening is shown in Table 3 . in patients receiving primary antifungal mould prophylaxis (Table 3) .
Materials and methods
U K W H E L MUI To tal A M L (n) 42 24 33 99 A L L (n) 7 5 6 18 C L L (n) 6 0 0 6 M D S (n) 203 3 26 Lymphoma (n) 17 3 1 21 MM (n) 37 0 1 38 Solid tumours (n) 0 5 0 5 H S C T (n) 119 40 44 203 Male/female ratio (n) 82
D ia g n o stic p a ra m e te rs
The data gained from probable IA cases demonstrate that a biomarker screening approach is meaningful for patients who are not receiving primary antifungal mould prophylaxis ( Table 2 ). The PPV for double PC R positivity was 62.5%. A major finding of this study is the fact that PC R resulted in a high ratio of false positivity in patients receiving antifungal mould prophylaxis. P C R was positive in 45.5% of patients with no IFD/ IA according to EO RTC /M SG criteria. In contrast, U K W showed low levels of false-positive PC R results (7.7%) ( Table 4 ).
However, in general, a high N P V was found for both strategies applied, both without (98.3%) and with (100%) antifungal
prophylaxis.
Discussion
In our study, the incidence rates of proven and probable IA (Table 4) .
Overall, only 2.4% of patients from the M UI and H EL were categorized as suffering from possible IA, in contrast to 27.9% of patients from U K W .
The primary aim of our study was to determine whether PC R targeting fungal D N A extracted from serum could in crease the diagnostic accuracy for detection of IA in high-risk patients. O n the basis of the encouraging results of an earlier study, we selected a PC R assay [22] in which the use of serum is expected to produce fewer false-negative results, owing to the smaller amount of host D N A [23, 24] , W e focused on unifying all technical procedures to ensure in-house Aspergillus PC R reliability in the appointed study centres. It is striking that the PPV of the in-house Aspergillus PC R assays was relatively low (5.4%) in patients receiving antifungal mould prophylaxis, whereas it was sufficient (62.5%) in patients without antifungal prophylaxis ( Table 3) To obtain reliable PC R results, the highest-quality standards were applied in this survey. D N A processing was compliant with EA PC RI recommendations [17] , and internal quality con 
